Why Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is a biotech force to be reckoned with Regeneron was founded in 1988 by Dr. Leonard S Schleifer. Dr. Schelifer shared, that the name Regeneron came from “Regenerating neurons, with the word “gene” in the middle”. The origin of the name further explains that the initial focus of the company was neurobiology. Then in 1990 following the publication
Alnylam Pharmaceuticals (NASDAQ: ALNY) Stock Deep Dive Founded in 2002, Alnylam has led the commercialization of RNAi. However, the company has faced multiple battles on its way here. After the initial hype of RNA technologies faded in the 2010s, many RNAi companies faced a downturn as the industry quickly lost confidence in the ability to commercialize RNA-based
A Biotech Growth Stock to Consider For Your Portfolio - Sarepta Therapeutics (NASDAQ: SRPT) Sarepta Therapeutics (NASDAQ:SRPT) was founded by Marwan Fawaz in 1980 with the mission of developing precision genetic medicines for the treatment of rare neuromuscular diseases. Fast forward to 2022 and Sarepta Therapeutics is a pioneer in Duchenne muscular dystrophy (DMD) therapy with three FDA-approved RNA therapies to treat this